DDDR-29. THE HYDROGEL-CXCL9-MRNA (HCM) VACCINE RESULTS IN SIGNIFICANT ANTI-TUMOR EFFICACY THROUGH RECRUITMENT OF NATURAL KILLER (NK) CELLS

Abstract INTRODUCTION: Immunotherapy for GBM has resulted in limited benefits to overall survival due the targeting of antigens and hostile TME. Our group developed a patented vaccine platform that combines an mRNA-nanoparticle with CXCL9 loaded polyethylene glycol (PEG) hydrogel. The HCM is given SQ recruits diverse immune cell population deliver large payload mRNA. objective these studies was evaluate efficacy mechanisms action vaccine. METHODS: C57BL/6 mice underwent intracranial implantation KR158 glioma cells. formulated total tumor mRNA, DOTAP, PEG hydrogel created collaboration College Engineering. Survival were analyzed Mantel-Cox test. Flow cytometry ELISA data using ANOVA. Graphpad used statistical analysis. RESULTS: KR158-glioma bearing treated injection (total CXCL9, hydrogel). animals are resistant treatment radiation, temozolomide other immunotherapy platforms our laboratory. Treatment lived significantly longer compared control (35 days versus 22 days, p < 0.0001). In separate experiment, fat pad collected after vaccination flow revealed recruitment dendritic cells (DCs), CD4 CD8 T NK Large numbers antigen specific found spleen within TME vaccination. When blocked (NK 1.1 blocking antibody), benefit from completely abrogated. increase presentation available IFN-gamma scaffold. CONCLUSION: demonstrates murine models dependent on at site